Welcome to our dedicated page for Moleculin Biotec news (Ticker: MBRX), a resource for investors and traders seeking the latest updates and insights on Moleculin Biotec stock.
Moleculin Biotech, Inc. (Nasdaq: MBRX) is a Phase 3 clinical stage pharmaceutical company whose news flow is driven by developments in its oncology and virology pipeline. The company regularly issues updates on its lead anthracycline program Annamycin (naxtarubicin), its Immune/Transcription Modulator WP1066, and its antimetabolite portfolio, including WP1122.
News about Moleculin often focuses on clinical trial milestones, particularly for the pivotal, adaptive design Phase 2B/3 MIRACLE trial in relapsed or refractory acute myeloid leukemia (AML). Investors can follow announcements on enrollment progress, interim unblinding plans, trial expansion across multiple countries, and independent assessments of Annamycin’s cardiotoxicity profile. The company has highlighted an independent expert review of 90 Annamycin-treated subjects across five trials with no evidence of cardiotoxicity based on ECG, echocardiography and cardiac biomarkers.
Another key news theme is pipeline expansion. Moleculin reports investigator-initiated and grant-funded research that extends Annamycin into pancreatic cancer and glioblastoma multiforme (GBM), including collaborations with UNC-Chapel Hill and CIC biomaGUNE. Updates also cover externally funded clinical activity for WP1066 in adult GBM at Northwestern University and pediatric brain tumors at Emory University, along with published Phase 1 data showing STAT3 suppression and anti-tumor immune responses in children.
Moleculin’s news stream also includes corporate and regulatory updates such as reverse stock split actions, Nasdaq listing compliance developments, warrant exercises and patent grants, including an Australian patent for preliposomal Annamycin lyophilizate. For investors tracking MBRX, this news page provides a centralized view of scientific, clinical, regulatory and capital markets announcements related to the company’s efforts in hard-to-treat cancers and certain viral infections.
Moleculin Biotech, Inc. (Nasdaq: MBRX) will report its Q1 2024 financial results on May 10, 2024. The company focuses on drug candidates for hard-to-treat tumors and viruses. A conference call and webcast to discuss the results will be held on May 13, 2024, at 8:30 AM ET.
Moleculin Biotech, Inc. reports positive interim data for Annamycin in treating acute myeloid leukemia (AML). The CRc rate reached 62% in 1st and 2nd line AML subjects, with a 45% CRc in the full MB-106 trial. The presentation of data supports advancing to a Phase 2 trial (MB-108) for potential New Drug Approval. A virtual AML Clinical Day was held on May 7, 2024. Key data shows promising results and progression towards registration for Annamycin in AML.
Moleculin Biotech, Inc. (Nasdaq: MBRX) will host a virtual AML Clinical Day featuring Dr. Martin Tallman, discussing the unmet medical needs in AML treatment, Annamycin, and the Company's AML clinical development program. The event will highlight the ongoing progress of Annamycin towards a pivotal AML study in 2024 for potential accelerated approval.
Moleculin Biotech, Inc. announced the formation of its Annamycin Scientific Advisory Board, appointing Dr. Martin Tallman as the inaugural clinician member. Dr. Tallman, an internationally renowned clinician, brings extensive experience in leukemia-targeting therapies. The company aims to advance the development of Annamycin, a promising treatment for AML and STS lung mets.
FAQ
What is the current stock price of Moleculin Biotec (MBRX)?
What is the market cap of Moleculin Biotec (MBRX)?
